Activated Clotting Time‐Guided Systemic Heparinization as One Component of a Stepwise Salvage Algorithm for Inadequate Internal Mammary Artery Flow in Microsurgical Breast Reconstruction Authors: Kazuhiro Tsunekawa, Daisuke Yanagisawa, Shunsuke Yuzuriha Published: 2026 ABSTRACT ABSTRACTBackgroundThe internal mammary vessels are commonly used as recipient vessels for free flap breast reconstruction. However, inadequate arterial flow may be encountered intraoperatively. This hypothesis‐generating study evaluated the safety and feasibility of activated clotting time (ACT)‐guided systemic heparinization as one component of a salvage strategy in such situations.MethodsWe retrospectively reviewed consecutive autologous breast reconstructions using the internal mammary artery (IMA) between 2019 and 2025. Based on intraoperative jet bleeding status and intimal findings, IMA vessels were categorized into three groups: normal flow, inadequate flow managed by conventional measures, and inadequate flow subsequently managed by ACT‐guided systemic heparinization. ACT‐guided systemic heparinization targeted an ACT of 200 s. An initial heparin bolus infusion of 36–60 IU/kg was given, followed by ACT measurement 15–30 min later and every 30–60 min thereafter, with additional heparin administered for ACT ≤ 200 s. Clinical outcomes were evaluated and compared.ResultsA total of 103 IMA vessels (101 patients) were analyzed: 80 (77.7%) in the normal flow group, 17 (16.5%) in the inadequate flow group, and 6 (5.8%) in the ACT‐guided heparinization group. Patient characteristics, aortic calcification, IMA diameter, and blood loss did not differ among groups (all p > 0.05). Postoperative hematoma rate was 2/80 for normal flow, 0/17 for inadequate flow, and 0/6 for ACT‐guided heparinization (p > 0.05). Median peak ACT was 238 s, and median intraoperative heparin dose was 4758 IU. Despite the significantly longer intraoperative flap ischemia time in the ACT‐guided heparinization group (normal flow: 98.5 min, inadequate flow: 127 min, ACT‐guided heparinization: 208 min; p < 0.01), all six flaps survived.ConclusionsAs part of intraoperative rescue, ACT‐guided systemic heparinization was employed successfully in 5.8% of IMA vessels in this series. ACT monitoring provides rapid and objective assessment and may represent an additional intraoperative option for suboptimal arterial flow.Keywords: activated clotting time, breast reconstruction, internal mammary artery, microsurgery, systemic heparinization, unfractionated heparin Introduction Breast reconstruction after mastectomy for breast cancer can be performed using autologous tissue free flaps. A variety of recipient vessels have been employed for free flap breast reconstruction, including the thoracodorsal vessels (Moran et al. 2003; Samargandi et al. 2017), circumflex scapular vessels (Lantieri et al. 1999), lateral thoracic vessels (Muto et al. 2023), internal mammary perforator vessels (Saint Cyr et al. 2007), and internal mammary vessels (O'Neill et al. 2016; Nahabedian 2012). The advantages and disadvantages of each vessel have been well described. The internal mammary artery (IMA) is one of the most common recipient arteries in breast reconstruction (O'Neill et al. 2016; Nahabedian 2012). This vessel features a favorable diameter (2.0–3.0 mm) that closely matches that of deep inferior epigastric perforator (DIEP) flap vessels, minimal anatomical variation, ease of flap positioning and esthetics, sufficient blood flow, and enables the preservation of the thoracodorsal vessels for potential future reoperation or salvage surgery (O'Neill et al. 2016; Nahabedian 2012). The disadvantages of the IMA include the potential need for costal cartilage resection, blood loss, the risk of pleural or pericardial injury, and the loss of the IMA as a potential conduit for future coronary artery bypass grafting (O'Neill et al. 2016; Nahabedian 2012). In most cases, arterial flow from the IMA during breast reconstruction surgery is satisfactory. However, surgeons occasionally encounter situations in which sufficient arterial inflow cannot be obtained at the time of vessel division (He and Taggart 2016), possibly due to spasm (He et al. 1989, 1995), hypothermia (Bodelsson et al. 1991), mechanical injury during vessel dissection (Suma et al. 1991), or intimal thickening/fragility (Ruengsakulrach et al. 1999). The standard countermeasures against poor arterial flow include warming with saline, topical or intraluminal administration of papaverine to induce vascular smooth muscle relaxation, intraluminal irrigation with heparinized saline, and additional proximal vessel dissection. In the majority of cases, these interventions restore adequate flow within several to approximately 10 min. Nevertheless, instances of unsuccessful restoration exist. In such situations, reports from the field of head and neck cancer reconstruction have described the successful completion of vascular anastomosis following intraoperative intravenous bolus administration of heparin (Grill et al. 2024; Kallenberger et al. 2023; Biermann et al. 2024), although a standardized heparin dose has not been established since activated partial thromboplastin time (APTT) values vary, even under the same dose of heparin (Bern 1975; Cronin and Reilly 2010). In cardiovascular surgery using cardiopulmonary bypass circuits, systemic heparinization guided by target activated clotting time (ACT) values is standard practice (Shore‐Lesserson et al. 2018; Khalil et al. 2024). However, there is currently no established consensus on the use of ACT‐guided anticoagulation or target ACT values in free flap reconstruction. The present hypothesis‐generating study evaluated cases in which systemic heparinization was performed with reference to ACT values during free flap breast reconstruction using the IMA as the recipient vessel. We aimed to clarify the safety and feasibility of a stepwise intraoperative approach with ACT‐guided systemic heparinization in this clinical setting. Methods This retrospective, single‐center, observational study screened the medical data of 107 consecutive patients who underwent free flap breast reconstruction using the internal mammary vessels as recipient vessels at Shinshu University Hospital between January 2019 and December 2025. All procedures were performed by 2 board‐certified plastic surgeons (K.T. and D.Y.). The inclusion criteria comprised immediate or delayed breast reconstruction following mastectomy for breast cancer or prophylactic mastectomy for hereditary breast cancer and ovarian cancer. The exclusion criteria included refusal to participate in the study, incomplete data, and follow‐up of less than 6 months. For this study, the unit of analysis was set as the recipient IMA rather than the patient. Surgical Technique Free flap breast reconstruction was primarily performed using DIEP flaps, free transverse rectus abdominis muscle flaps, or profunda artery perforator flaps. The ipsilateral IMA and internal mammary vein (IMV) were employed as recipient vessels, typically at the third or fourth intercostal space. After removal of the costal cartilage, the IMA and IMV were ligated at the distal side and temporarily occluded with microvascular clamps prior to cutting. The conditions of pulsatile jet‐like bleeding from the IMA and the intimal surface were evaluated before anastomosis. Inadequate blood flow was defined as diminished or absent pulsatile jet‐like bleeding from the cut end of the IMA. Intimal abnormality was judged as marked intimal thickening, fragility, easy separation from the vessel wall, or an irregular/friable intimal surface on intraoperative inspection. Vascular anastomosis was performed according to the following stepwise protocol based on the bleeding characteristics from the cut end of the IMA (Figure 1). First, the distal IMA was transected and its bleeding pattern and intimal condition were assessed. If strong pulsatile jet‐like bleeding was observed from the cut end, the vessel was trimmed to an appropriate length and arterial anastomosis was performed (normal IMA flow group). However, if pulsatile bleeding was diminished, the artery was progressively trimmed proximally toward the cranial side by several millimeters at a time. Such trimming was limited to a level that would not interfere with the anastomosis due to the overlying costal cartilage. After transection of the IMA, the intimal surface was also inspected. If any thickening or fragility was observed, the artery was similarly trimmed proximally until a smooth intimal surface was identified, again with the restriction of no anastomosis hindrance by the costal cartilage. In both cases, the artery was warmed with saline, papaverine hydrochloride was applied topically, and the lumen was irrigated with heparinized saline. Anastomosis was performed once adequate pulsatile bleeding was confirmed (inadequate IMA flow group). Lastly, if adequate jet‐like bleeding was not observed after approximately 10 min despite conventional rescue measures and/or if marked intimal abnormalities were considered to pose a high risk of thrombosis after proximal trimming produced an arterial stump considered suitable for anastomosis, systemic heparinization was requested from the anesthesiologist with a target ACT of approximately 200 s before arterial anastomosis (ACT‐guided heparinization group). ACT‐guided heparinization was also performed when arterial patency could not be achieved despite two attempts of arterial anastomosis. Stepwise intraoperative assessment of arterial inflow prior to anastomosis. Before arterial anastomosis, pulsatile jet bleeding from the internal mammary artery (IMA) and intimal condition were assessed. When adequate jet bleeding and a normal intima were observed, anastomosis was performed (normal IMA flow group). In cases of diminished or absent jet bleeding or intimal abnormality, proximal trimming and adjunctive measures including saline warming, topical papaverine, and heparinized saline irrigation were performed as conventional measures (*); if flow improved, anastomosis was completed (inadequate IMA flow group). When flow did not recover after approximately 10 min or patency was not achieved after 2 attempts, systemic heparinization targeting an activated clotting time (ACT) of approximately 200 s was performed (ACT‐guided heparinization group). Following arterial anastomosis, pulsation of the flap artery was confirmed by palpation. If present, indocyanine green angiography was performed approximately 30 min later to verify the patency of the anastomosis. After confirming vascular patency, the flap was inset and breast shaping was performed. ACT‐Guided Systemic Heparinization The initial heparin bolus dose was determined according to body weight by the anesthesiologist and subsequently adjusted based on serial ACT measurements. ACT was first assessed 15–30 min following the initial bolus infusion. Measurements were repeated every 30–60 min until stable arterial patency was maintained. When ACT was ≤ 200 s, heparin was added either as a bolus infusion or a continuous drip. In cases with satisfactory flap perfusion confirmed by indocyanine green angiography approximately 30 min after completing microvascular anastomosis, the attending surgeon discontinued systemic heparinization. Protamine reversal was not used; the surgeon waited for the natural diminishing anticoagulative effects by the patient's metabolism. Hemostasis was confirmed clinically by the operation team, and ACT normalization was not required before wound closure. Postoperative Management Postoperative systemic heparinization was continued in selected cases at the discretion of the surgeon. The duration and dosage of administration were determined on a case‐by‐case basis. Patients were closely monitored for postoperative bleeding, hematoma formation, and flap perfusion. Otherwise, systemic heparinization was limited to intraoperative administration based on the surgeon's intraoperative judgment. Study Design Cases were retrospectively classified into three groups based on the intraoperative findings and management documented in operative records according to our institutional stepwise management protocol (Figure 1) into the normal IMA flow group, inadequate IMA flow group, and ACT‐guided heparinization group. Outcome Measures Collected data included patient characteristics, preoperative computed tomography (CT) findings and laboratory test results, as well as postoperative outcomes and complications. In the ACT‐guided heparinization group, the initial heparin bolus dose, number of heparin bolus injections, total heparin dose, and measured ACT values were also recorded. The primary outcomes in this study were flap outcome, incidence of intraoperative inadequate IMA flow, and proportion of cases requiring systemic heparinization. Secondary outcomes included IMA diameter at the planned anastomotic site on preoperative CT, postoperative flap thrombosis, postoperative hematoma, intraoperative blood loss, number of arterial revisions, flap ischemia time, and number of patients requiring blood transfusion. We also evaluated Khorana score as determined by preoperative laboratory data, body mass index (BMI), and cancer type (Mulder et al. 2019). The degree of calcification of the descending thoracic aorta on preoperative CT was assessed and categorized as none, partial, or diffuse. The presumed cause of inadequate IMA flow was retrospectively identified from operative records and categorized as vasospasm, intimal thickening/fragility, or unknown. Statistical Analysis Continuous variables are presented as the mean ± standard deviation or median with range as appropriate. Categorical variables are presented as the count and percentage. Continuous variables were compared using the Kruskal–Wallis test, whereas categorical variables were compared with the Fisher–Freeman–Halton exact test. Statistical significance was set at a p < 0.05. All statistical analyses were performed using IBM SPSS version 29.0 software (IBM Corp., NY). The study has been checked against the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist (Supplementary Appendix 1). Ethical Considerations This study was approved by the institutional review board (no. 6765), and written informed consent was obtained from all patients. Results Results are presented in the order of “normal IMA flow group, inadequate IMA flow group, ACT‐guided heparinization group” unless otherwise specified. Of the 107 consecutive patients screened, 101 satisfied the inclusion criteria. Six patients were excluded due to refusal to participate (n = 2), incomplete data (n = 2), and follow‐up of less than 6 months (n = 2). Two patients underwent bilateral reconstruction, resulting in a total of 103 recipient IMA vessels available for analysis. Based on the intraoperative assessment of IMA flow (Figure 1), the cases were categorized into the normal IMA flow group (80 vessels in 78 patients), inadequate IMA flow group (17 vessels in 17 patients), and ACT‐guided heparinization group (6 vessels in 6 patients). Additional intraoperative management was required for 23 of 103 arteries (22.3%) before arterial anastomosis. In the inadequate IMA flow group, the presumed causes were vasospasm in 3 cases, intimal abnormalities in 13 cases, and unknown in 1 case. In the ACT‐guided heparinization group, intimal abnormalities were identified in all 6 cases. Using conventional measures or intraoperative systemic heparinization, satisfactory IMA and IMV patency was achieved in all cases. The patient cohort (n = 101) is summarized in Table 1. Patient characteristics did not differ significantly among the groups for age, BMI, Khorana score, or the degree of thoracic calcification. No patient had undergone previous thoracic surgery other than breast cancer surgery. Patients with radiation therapy to the chest wall before reconstruction totaled 6 in the normal IMA flow group and 1 in the inadequate IMA flow group, with none in the ACT‐guided heparinization group. TABLE 1Patient characteristics.Normal IMA flow patients (n = 78)Inadequate IMA flow patients (n = 17)ACT‐guided heparinization patients (n = 6) p Age (years, mean ± SD)50.6 ± 6.551.9 ± 8.150.7 ± 9.50.77BMI (kg/m2, mean ± SD)23.5 ± 3.624.6 ± 6.124.0 ± 2.90.94ComorbiditiesHypertension8 (10%)5 (29.4%)01.00Hyperlipidemia7 (9%)1 (5.9%)2 (33.3%)1.00Diabetes mellitus001 (16.7%)1.00Vascular disease2 (3%)001.00Previous thoracic surgery other than breast cancer surgery000Smoking1.00Current2 (3%)1 (5.9%)1 (16.7%)Previous18 (23%)4 (23.5%)3 (50%)Never58 (74%)12 (70.6%)2 (33.3%)Affected side1.00Right36 (46%)8 (47%)3 (50%)Left41 (53%)9 (53%)3 (50%)Bilateral1 (1%)00Contralateral prophylactic resection1 (1%)00Breast surgery a 1.00NSM4 (5%)3 (17.6%)0SSM3 (4%)1 (5.9%)0Total mastectomy73 (91%)13 (76.5%)6 (100%)Axillary surgery a 1.00SLND59 (74%)13 (76.5%)6 (100%)ALND19 (24%)4 (23.5%)0None2 (2%)00Radiation therapy to the chest wall before reconstruction6 (8%)1 (5.9%)01.00Chemotherapy29 (37%)4 (23.5%)1 (16.7%)1.00Adjuvant endocrine therapy1.00SERM28 (36%)8 (47%)2 (33.3%)Non‐steroidal AI17 (22%)2 (11.8%)0Steroidal AI1 (1%)1 (5.9%)0GnRH agonist7 (9%)2 (11.8%)0Khorana score1.00074 (95%)15 (88.2%)6 (100%)14 (5%)2 (11.8%)0≥ 2000Descending thoracic aorta calcification1.00None64 (82%)13 (76.5%)5 (83.3%)Partial14 (18%)4 (23.5%)1 (16.7%)Diffuse000 Note: Due to two patients undergoing bilateral breast reconstruction, the totals for the affected side, breast surgery, and axillary surgery exceed the number of patients.Abbreviations: ACT, activated clotting time; AI, aromatase inhibitors; ALND, axillary lymph node dissection; BMI, body mass index; IMA, internal mammary artery; NSM, nipple‐sparing mastectomy; SD, standard deviation; SERM, selective estrogen receptor modulator; SLND, sentinel lymph node dissection; SSM, skin‐sparing mastectomy. a Breast surgery refers to the type of mastectomy (NSM, SSM, or total mastectomy). Axillary surgery refers to the type of axillary procedure (SLND, ALND, or none). Patient characteristics. Note: Due to two patients undergoing bilateral breast reconstruction, the totals for the affected side, breast surgery, and axillary surgery exceed the number of patients. Abbreviations: ACT, activated clotting time; AI, aromatase inhibitors; ALND, axillary lymph node dissection; BMI, body mass index; IMA, internal mammary artery; NSM, nipple‐sparing mastectomy; SD, standard deviation; SERM, selective estrogen receptor modulator; SLND, sentinel lymph node dissection; SSM, skin‐sparing mastectomy. Breast surgery refers to the type of mastectomy (NSM, SSM, or total mastectomy). Axillary surgery refers to the type of axillary procedure (SLND, ALND, or none). The anastomotic level of the IMA (n = 103), vessel diameter, postoperative flap outcomes, complications, number of arterial revisions, flap ischemia time, and intraoperative blood loss are presented in Table 2. In all groups, anastomosis at the third intercostal space was more common than at the fourth space. Arterial diameter showed no significant difference across the groups (2.2 [1.5–3.1], 2.0 [1.2–2.9], and 2.0 [1.0–2.6] mm; p = 0.134). However, flap ischemia time was significantly longer in the ACT‐guided heparin group (98.5 [54–269], 127 [72–294], and 208 [96–355] min; p < 0.01). Intraoperative blood loss tended to be higher in the ACT‐guided heparinization group with no significant difference across the groups (199 ± 114, 211.8 ± 96L, and 230 ± 141 mL; p = 0.616), although postoperative hematoma rates did not vary remarkably. One patient in the normal flow group required blood transfusion due to severe anemia caused by hematoma at the abdominal donor site. Reoperation due to vascular complications was recorded in 2 cases in the normal flow group, both from venous thrombosis. No vascular complications were noted in the inadequate flow or ACT‐guided heparinization groups. Regarding flap outcomes, one case of total flap loss and four cases of partial necrosis occurred in the normal flow group. The case of total necrosis resulted from postoperative venous thrombosis. Among the four cases of partial flap necrosis, three cases were considered attributable to using the part of the flap beyond the dominant vascular territory, whereas the remaining case was associated with postoperative wound infection. Two cases of fat necrosis were observed in the inadequate flow group. No flap necrosis occurred in the ACT‐guided heparinization group. TABLE 2Anastomotic vessel characteristics and postoperative outcomes of IMA flow groups.Normal IMA flow vessels (n = 80)Inadequate IMA flow vessels (n = 17)ACT‐guided heparinization vessels (n = 6) p Flap type1.00DIEP70 (87.5%)16 (94.1%)5 (83.3%)TRAM9 (11.3%)1 (5.9%)1 (16.7%)PAP1 (1.2%)00IMA/IMV anastomotic level1.00Third intercostal space54 (67.5%)11 (64.7%)5 (83.3%)Fourth intercostal space26 (32.5%)6 (35.3%)1 (16.7%)Diameter of IMA (mm, median [range])2.2 (1.5–3.1)2.0 (1.2–2.9)2.0 (1–2.6)0.134Number of arterial revisions at anastomosis1.00074 (92.5%)11 (64.7%)3 (50%)16 (7.5%)5 (29.4%)0201 (5.9%)1 (16.7%)3002 (33.3%)Intraoperative blood loss (mL, mean ± SD)199 ± 114211.8 ± 96230 ± 1410.616Flap ischemia time (min, median [range])98.5 (54–269)127 (72–294)208 (96–355)< 0.01Postoperative hematoma2 (2.5%)001.00Reoperation for anastomotic revision2 (2.5%)001.00Blood transfusion1 (1.2%)001.00Flap outcome1.00Complete survival75 (93.7%)15 (88.2%)6 (100%)Partial necrosis4 (5%)00Total flap loss1 (1.2%)00Fat necrosis02 (11.8%)0 Note: Due to two patients undergoing the bilateral breast reconstruction, the totals for recipient vessels and flap outcomes exceed the number of patients.Abbreviations: ACT, activated clotting time; DIEP, deep inferior epigastric perforator; IMA, internal mammary artery; IMV, internal mammary vein; PAP, profunda artery perforator; SD, standard deviation; TRAM, transverse rectus abdominus muscle. Anastomotic vessel characteristics and postoperative outcomes of IMA flow groups. Note: Due to two patients undergoing the bilateral breast reconstruction, the totals for recipient vessels and flap outcomes exceed the number of patients. Abbreviations: ACT, activated clotting time; DIEP, deep inferior epigastric perforator; IMA, internal mammary artery; IMV, internal mammary vein; PAP, profunda artery perforator; SD, standard deviation; TRAM, transverse rectus abdominus muscle. Detailed information on the six cases in the ACT‐guided heparinization group is shown in Table 3. Median initial heparin bolus dose was 3000 IU (range: 2000–4000 IU), corresponding to 46.7 IU/kg (range: 36.2–61.4 IU/kg), and median total intraoperative heparin dose was 4758 IU (range: 2000–8387 IU). Median peak ACT during surgery was 238 s (range: 193–298 s). Postoperative continuous heparin administration was conducted in two cases. Case 6 demonstrated the most severe intimal thickening and fragility and was considered to harbor a particularly high risk of thrombosis. Therefore, we continued systemic heparinization for 4 days postoperatively. Case 1 received postoperative heparinization due to repeated loss of arterial pulsation approximately 20 min after anastomosis despite multiple attempts at reanastomosis. Therefore, we adjusted target ACT to 250 s and continued systemic heparinization for 3 days postoperatively. In the remaining 4 cases, systemic heparinization was limited to intraoperative administration. Postoperative APTT monitoring was performed only in the two patients who received continuous heparinization. The remaining four patients did not undergo postoperative APTT assessment. No postoperative hematoma or anastomotic complications were observed, and all flaps showed complete survival. TABLE 3Perioperative heparin administration and ACT values in the ACT‐guided heparinization group.CaseAge (years)BMI (kg/m2)Initial heparin bolus (IU)Initial heparin dose (IU/kg)Number of bolusesContinuous infusion intraoperativelyTotal intraoperative heparin (IU)Peak ACT (s)Postoperative heparinizationIntraoperative bleeding (mL)Postoperative hematomaFlap outcome14720.3200036.73Yes83872985000 IU/day until POD 3150NoComplete survival24326.8400061.41No4000286None200NoComplete survival35024.4400060.32No6000238None200NoComplete survival45127.8300045.12No4000238None470NoComplete survival54422.3300048.33No6000216None60NoComplete survival66922.2200036.21No200019310,000 IU/day until POD 4300NoComplete survivalMedian (range)48.5 (43–69)23.3 (20.3–27.8)3000 (2000–4000)46.7 (36.2–61.4)2 (1–3)N/A5000 (2000–8387)225 (175–280)N/A200 (60–470)N/AN/AAbbreviations: ACT, activated clotting time; BMI, body mass index; IU, international unit; N/A, not applicable; POD, postoperative day. Perioperative heparin administration and ACT values in the ACT‐guided heparinization group. Abbreviations: ACT, activated clotting time; BMI, body mass index; IU, international unit; N/A, not applicable; POD, postoperative day. Discussion In the present study, additional intraoperative management was required in 23 of 103 IMA cases (22.3%) due to inadequate pulsatile flow or intimal abnormalities prior to microvascular anastomosis. Among all cases, systemic heparinization guided by ACT was required for six arteries (5.8%), and all corresponding flaps survived in this limited series. Patient characteristics including age, BMI, smoking history, past medical history, Khorana score, oncologic treatment history, breast surgery type, axillary surgery type, and radiation therapy before reconstruction displayed no significant differences among the groups. Fat necrosis occurred in two cases in the inadequate IMA flow group. One case had the longest flap ischemia time in this group (294 min), which suggested that prolonged ischemia associated with technically challenging recipient vessel conditions might have contributed to this outcome. However, fat necrosis was not observed in the ACT‐guided heparinization group despite a similarly prolonged flap ischemia time. Therefore, ischemia time alone may not fully account for this difference. Although factors related to flap vascular territory and perfusion characteristics may also have influenced the outcome, definitive conclusions cannot be drawn from the present series. The other case of fat necrosis was associated with vasospasm. However, whether vasospasm directly contributed to this result was unclear, and the exact mechanism could not be determined. Without larger cohorts, no conclusive interpretations can be made regarding the relationship between inadequate IMA flow and fat necrosis. Intraoperative blood loss tended to be higher in the ACT‐guided heparinization group, although no apparent increase in postoperative hematoma formation or requirement for blood transfusion was observed in this limited series. Moreover, no postoperative vascular complications were recorded in the ACT group, and all flaps survived. The IMA is widely used as a recipient vessel in free flap breast reconstruction owing to its stable inflow, favorable diameter, and minimal anatomical variation (He et al. 1989, 1995). However, inadequate arterial inflow may be encountered during vessel preparation (He et al. 1989, 1995; Bodelsson et al. 1991; Suma et al. 1991; Ruengsakulrach et al. 1999). In the present series, approximately one quarter of IMA vessels required some form of intraoperative intervention to obtain satisfactory inflow. As the degree of aortic calcification on preoperative CT, IMA diameter, and Khorana score did not differ substantially among the groups, the predictive factors of poor pulsatile jet flow and unfavorable intimal conditions are not possible in this study. Potential causes of reduced arterial flow include mechanical trauma during dissection, intimal abnormalities, and vasospasm (He et al. 1989, 1995; Suma et al. 1991; Ruengsakulrach et al. 1999). When pulsatile jet bleeding is insufficient or intimal conditions are unfavorable for the IMA, initial restorative attempts should be made using conventional measures, including saline warming, topical papaverine, intraluminal irrigation with heparinized saline, and additional proximal trimming of the vessel. In this study, all cases in the ACT‐guided heparinization group indicated intimal abnormalities, which differed from the inadequate flow group. Flap ischemia time was significantly longer in the ACT‐guided heparinization group versus the other groups as well. This finding likely reflected the greater technical complexity of these cases due to severe intimal abnormalities, repeated arterial revisions, and the need for additional intraoperative intervention. When considering a stepwise approach to pathology, less invasive corrective approaches such as additional vessel trimming, saline washing, and papaverine (Geierlehner et al. 2025) should generally first be employed as established management strategies. Then, systemic heparinization may next be considered as a bridging option before more invasive alternatives. Since technical revision of anastomosis, recipient vessel conversion, arteriovenous loop surgery, and changing the intercostal level may prolong operative time, require additional dissection, or increase flap ischemia time, our strategy is aimed to help restore patency within the same recipient field whenever possible. From this perspective, ACT‐guided systemic heparinization should be regarded not as a routine anticoagulation strategy, but as an additional option in cases of conventional measure failure before proceeding to more invasive measures. From a pharmacological perspective, unfractionated heparin suppresses fibrin clot formation without inhibiting platelet aggregation. Therefore, the direct effectiveness of systemic heparinization in this situation remains uncertain. However, this approach may contribute to flow stability immediately post‐anastomosis by preventing secondary thrombus formation. Further investigation is warranted to determine the optimal duration and indications for systemic heparinization following microvascular anastomosis. Several pharmacologic strategies have been proposed to reduce thrombosis in microsurgical reconstruction, including aspirin (Khan and Tayeb 2023; Karamanos et al. 2022), low‐molecular‐weight heparin (LMWH) (Yousef and Dionigi 2015; Murthy et al. 2006), and unfractionated heparin (Numajiri et al. 2016; Pan et al. 2014; Biermann et al. 2024). Aspirin and LMWH are commonly used in microsurgery but have limited applicability for intraoperative titration. In contrast, unfractionated heparin can be promptly adjusted under ACT monitoring to enable objective anticoagulation assessment during surgery. In patients without systemic anticoagulation, ACT values are generally 80–120 s (Hussein et al. 2012). During cardiac surgery with cardiopulmonary bypass, ACT is commonly maintained above 400–480 s (Shore‐Lesserson et al. 2018), whereas lower targets of approximately 250–300 s are generally used in off‐pump coronary artery bypass procedures (Chassot et al. 2004). High‐dose heparin has been associated with an increased risk of postoperative hematoma and higher flap loss rates, indicating that careful attention to dosing is required (Numajiri et al. 2016; Pan et al. 2014; Biermann et al. 2024). The target ACT of approximately 200 s in our series was chosen pragmatically to achieve moderate anticoagulation while avoiding excessive bleeding, rather than as a definitively established threshold for microsurgery. ACT monitoring has been widely utilized in cardiovascular and vascular surgery for real‐time assessment of anticoagulation, whereas reports in reconstructive microsurgery remain limited. Patel and Singhal (2015) described the use of ACT monitoring during osteocutaneous free fibula flap reconstruction and adopted a target ACT of approximately 200 s. Given the limited literature available in plastic surgery, we referred to this report when selecting our target ACT value. Systemic heparinization guided by ACT allowed for the adjustment of anticoagulation to a practical intraoperative level, with a median peak ACT of 238 s in the present series. Postoperative heparinization was continued in two selected patients due to persistent concern regarding arterial thrombosis. Systemic heparinization was limited to intraoperative administration in the remaining four cases. Several reports have suggested that routine postoperative heparin infusion does not improve flap survival and may increase the risk of hematoma formation (Numajiri et al. 2016; Pan et al. 2014; Biermann et al. 2024). ACT‐guided intraoperative heparinization may offer several practical advantages such as the rapid availability of anticoagulation status, objective numerical assessment, and enabling surgeons to focus on surgery while anticoagulation management is handled by anesthesiologists. One limitation of ACT is that its values vary depending on measurement conditions, including the device used, activation method, hematocrit, and platelet count (Hoebink et al. 2025). Furthermore, ACT is not specific to heparin activity and may be influenced by other factors, such as hypothermia, hemodilution, and coagulation factor depletion (Dalton et al. 2022). Based on our institutional experience, ACT‐guided systemic heparinization was considered in cases exhibiting persistently inadequate jet‐like bleeding despite conventional rescue measures and/or marked intimal abnormalities only when proximal trimming produced an arterial stump with an intimal condition suitable for anastomosis. Our approach was also indicated when arterial patency could not be achieved despite 2 attempts at arterial anastomosis. However, ACT‐guided systemic heparinization should not be applied when proximal trimming fails to provide an arterial stump amenable to anastomosis or when irreversible structural abnormalities of the recipient artery are present. In such situations, recipient vessel conversion should remain the primary salvage option. Limitations This investigation has several limitations. First, it was a retrospective single‐institution study with a small sample size, particularly in the ACT‐guided heparinization group, which limited the generalizability of our findings. Second, the assessment of inadequate IMA flow and intimal abnormalities relied primarily on intraoperative visual judgment and retrospective review of operative records; quantitative adjunctive methods such as Doppler flowmetry or objective perfusion analysis were not routinely employed. Therefore, some degree of subjective interpretation and classification bias cannot be excluded. Quantitatively assessing IMA flow with Doppler ultrasonography or flow measurements will improve the reproducibility of the algorithm. Third, the decision to perform systemic heparinization and postoperative anticoagulation was made at the discretion of the surgeon, which could have introduced treatment selection bias. Lastly, although statistical comparisons were performed, the small sample size, particularly in the ACT‐guided heparinization group, limited statistical power and precluded definitive conclusions. Conclusion ACT‐guided systemic heparinization may represent a feasible adjunctive option in cases of inadequate IMA flow during microsurgical breast reconstruction. This preliminary, hypothesis‐generating report suggests that intraoperative adjustment of unfractionated heparin dosing under ACT monitoring can provide a more objective and reproducible approach to systemic anticoagulation in selected situations. ACT‐guided heparinization may be considered as a bridging option prior to more invasive established salvage strategies such as recipient vessel conversion and arteriovenous loop creation. Further accumulation of data is necessary to clarify the appropriate indications, optimal ACT targets, heparin infusion protocols, postoperative outcomes, and potential complications of ACT‐guided systemic heparinization in microsurgical reconstruction. Funding The authors have nothing to report. Ethics Statement Institutional review board approval was obtained from Shinshu University School of Medicine (no. 6765). Conflicts of Interest The authors declare no conflicts of interest. Supporting information Supplementary Appendix 1. STROBE checklist for the present observational study. Acknowledgments The authors used Chat GPT exclusively for minor language editing and not for the generation or interpretation of scientific content. The manuscript was subsequently proofread by Mr. Trevor Ralph. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Supplementary Materials Supplementary Appendix 1. STROBE checklist for the present observational study. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.